Septerna, Inc. SEPN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
60/100
Moderate

Ranked against 712 peers in Biotechnology

About Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and … Full SEPN analysis →

Key strengths

  • Cash Generation Consistent Cash generation is consistent (score 0.99), indicating reliable business model.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.99).

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.00), raising refinancing risk.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.00), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
37
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where SEPN ranks in Biotechnology

Septerna, Inc. ranks #114 of 713 scored companies in Biotechnology by moat score — the top 16%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
110 AEON Biopharma, Inc. AEON 60/100 Moderate
111 Sarepta Therapeutics, Inc. SRPT 60/100 Moderate
112 MacroGenics, Inc. MGNX 60/100 Moderate
113 ArriVent BioPharma, Inc. AVBP 60/100 Moderate
114 Septerna, Inc. SEPN 60/100 Moderate
115 Tarsus Pharmaceuticals, Inc. TARS 60/100 Moderate
116 Phio Pharmaceuticals Corp. PHIO 60/100 Moderate
117 Climb Bio, Inc. CLYM 59/100 Moderate
118 Ascentage Pharma Group Internat AAPG 59/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How SEPN scores on the Corporate Default defenses

Pricing Power

Score 37 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 72 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 99 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 52 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 71 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 58 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SEPN's moat

What is Septerna, Inc.'s moat score?

Septerna, Inc. (SEPN) scores 60 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #114 of 713 scored companies in Biotechnology, the top 16%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (99/100) and its weakest is Pricing Power (37/100).

How does Septerna, Inc. compare with other Biotechnology companies?

Septerna, Inc. ranks #114 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are ArriVent BioPharma, Inc. (AVBP) at 60 just above it and Tarsus Pharmaceuticals, Inc. (TARS) at 60 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Septerna, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Septerna, Inc.?

The Corporate Default template measures 6 defenses, and SEPN scores: Pricing Power (37), Cost Advantage (72), Customer Stickiness (99), Capital Efficiency (52), Resilience (71), Scale & Market Position (58). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000